TAVR is safe for intermediate-risk patients

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Transcatheter aortic valve replacement (TAVR) is safe in patients with severe aortic stenosis (AS) at intermediate surgical risk, with similar rates of mortality and disabling stroke at 2 y as surgical aortic valve replacement (SAVR).
  • TAVR patients had more major bleeding, major vascular complications, and permanent pacemaker (PPM) implantation and SAVR patients had more acute kidney injury (AKI) and atrial fibrillation (Afib).

Why this matters

  • Although TAVR has been studied extensively in high-risk patients, randomized studies of intermediate-risk patients were lacking.

Study design

  • Surgical Replacement and Transcatheter Aortic Valve Implantation noninferiority, multicenter, randomized trial.
  • 1657 patients with severe AS at intermediate surgical risk underwent TAVR (n=863) or SAVR (n=794).
  • Funding: Medtronic.

Key results

  • At 30 d, TAVR group had higher rates of major bleeding (12.2% vs 9.3%), major vascular complications (6% vs 1.1%), and PPM implantation (25.9% vs 6.6%), but SAVR group had higher rates of AKI (4.4% vs 1.7) and Afib (43.4% vs 12.9%).
  • At 1 y, more moderate or severe residual paravalvular regurgitation in TAVR (5.3% vs 0.6%).
  • At 2 y, rate of all-cause mortality or disabling stroke was 12.6% in TAVR and 14% in SAVR.

Limitations

  • High number of withdrawals from SAVR group.